The facts
What the regulators actually say.
Official side-effect information, safety warnings and reporting routes for medicines, supplements, skincare and cosmetic procedures — written from NHS and MHRA public guidance, with the source and the date we last checked it on every section. Nothing here comes from the feed.
Not medical advice. This page summarises public guidance and points you to the authoritative documents. It cannot tell you whether a medicine is right for you, and it is not a substitute for your GP, pharmacist or prescriber. Last reviewed 12 November 2026.
How to use this page
The leaflet is the authority. This is the map.
Every medicine licensed in the UK arrives with a patient information leaflet, and that leaflet is the document regulators have signed off. It lists the side effects seen in trials and after launch, how common they are, and what to do about them.
The Facts exists to point you at that document, at the MHRA's safety updates, and at the NHS pages written for patients — and to tell you plainly where the community feed stops and official information begins.
We do not reproduce the whole leaflet, we do not rank medicines, and we do not tell anyone whether to start or stop a treatment. That conversation belongs to you and the clinician who prescribed it.
Source: MHRA — product information and Drug Safety Update · reviewed 12 November 2026
What is documented
Side effects come in tiers, and the tier matters
Official information separates side effects by how often they happen — very common (affecting more than one in ten people), common, uncommon, rare — and by how serious they are. That structure is why a leaflet can list nausea next to pancreatitis without equating them.
For GLP-1 medicines such as semaglutide and tirzepatide, the leaflets list gastrointestinal effects like nausea, vomiting, diarrhoea and constipation as very common, with serious but uncommon events including pancreatitis and gallbladder problems. New signals are added as regulators review them — the MHRA's Drug Safety Update is where those appear first.
For supplements, skincare products and cosmetic procedures, the picture is different again: regulation is lighter, evidence is thinner, and the most reliable information is usually the product's own ingredients list plus the MHRA's advice on buying medicines safely online.
- Always check the leaflet that came with your own pack — brand, strength and formulation can differ.
- The MHRA publishes label changes and new warnings as they happen, not when a product launches.
- A side effect being 'common' in a leaflet is a population statistic, not a prediction about you.
Source: MHRA — product information; GOV.UK Drug Safety Update · reviewed 12 November 2026
Reporting
The Yellow Card scheme is how patterns get found
The MHRA runs the Yellow Card scheme, which collects suspected side effects from patients as well as from clinicians. Reports from patients are explicitly welcome, and a report does not need to prove causation — suspicion is enough.
Yellow Card reports are how several current warnings reached the label in the first place. If something happened to you, reporting it takes a few minutes and asks for the product name, what happened, and roughly when.
This site cannot pass reports on for you, and a story posted here never reaches the regulator.
Source: MHRA Yellow Card scheme · reviewed 12 November 2026
Unlicensed and counterfeit
The grey market is where the worst stories come from
The MHRA and NHS have repeatedly warned about weight-loss injections, pens and 'skinny jabs' sold through social media, beauty salons and unregistered websites. Products sold this way may contain no active ingredient, the wrong ingredient, or an unsafe dose, and they carry no valid leaflet or batch number.
Prescription-only medicines are legally supplied against a prescription from a registered prescriber, dispensed by a registered pharmacy. If a seller offers a prescription medicine with no consultation and no prescriber, that is the warning sign.
For anything you have already bought, do not use it, keep the packaging, and report it — the MHRA takes reports on suspected falsified medicines.
Source: MHRA — falsified medicines guidance; NHS · reviewed 12 November 2026
When it is urgent
Some symptoms are not a wait-and-see
Severe or persistent abdominal pain, vomiting you cannot keep fluids down with, blood in vomit or stools, fainting, confusion, a racing heart, yellowing skin or eyes, or swelling of the lips, tongue or throat all need urgent assessment rather than a forum post.
Call 999 or go to A&E for severe symptoms. Use NHS 111 for urgent advice that is not an emergency. Your GP, pharmacist or the clinician who prescribed the medicine is the right contact for everything else.
Do not stop a prescribed medicine abruptly on the strength of something you read online — the MHRA advises talking to your prescriber first, because stopping can bring its own problems.
Source: NHS urgent and emergency care guidance · reviewed 12 November 2026
What this site is not
An account is not evidence of cause
Every experience in the feed is one person's memory, written by them, unpublished elsewhere and unverified here. If twenty people report hair loss after a medicine, that is twenty anecdotes — not a rate, not a prevalence, and not proof the medicine caused anything.
The counts on this site describe submissions to Side Effects. They are not clinical research, they are not a sample of the population, and they must never be read as the probability that a side effect will happen to you.
Where the community is useful is in preparation: knowing which questions to ask, what a symptom felt like for someone else, and that you are not the only person this happened to.
Source: Side Effects editorial policy; MHRA guidance on adverse reaction reporting · reviewed 12 November 2026
The sources we trust
Start with the leaflet in your own box, then these. If a claim about a medicine cannot be traced to one of them, treat it as somebody's opinion.
- NHS — medicines A to ZPlain-English information on individual medicines, including side effects.
- MHRA — product informationThe official patient information leaflet and summary of product characteristics for any licensed medicine in the UK.
- MHRA Yellow Card schemeReport a suspected side effect, including for herbal and unlicensed products.
- GOV.UK — Drug Safety UpdateThe MHRA's monthly bulletins on new safety signals and label changes.
- NHS 111Urgent medical advice when it is not a 999 situation.
Two more doors
The research desk tracks new GLP-1 studies and regulator decisions in plain English, with every source named. The safety centre is the short version for when something has already gone wrong.